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Tlr2 Deficiency is Associated with 
Enhanced Elements of Neuronal 
Repair and Caspase 3 Activation 
Following Brain Ischemia
Dunja Gorup1, Siniša Škokić1, Jasna Kriz2 & Srećko Gajović  1
The aim of this study was to apply multimodal in vivo imaging to assess the influence of altered 
innate immunity on brain repair after ischemic lesion. Tlr2-deficient mice were compared to wild type 
controls, as they lack Tlr2-mediated pro-inflammatory signaling triggered by postischemic necrosis. 
The ischemic lesion was induced by transient middle cerebral artery occlusion for 60 min, followed by 
brain imaging and analysis at four time points until 28 days after ischemia. Multimodal in vivo imaging 
involved a combination of 3 modalities: (1) magnetic resonance imaging by T2-weighted scans to 
assess brain lesion size, (2) bioluminescence imaging of Gap43-luc/gfp transgenic mice to visualize 
the axonal remodeling, and (3) caged-luciferin bioluminescence imaging of DEVD-luciferin allowing 
for visualization of caspase 3 and 7 activity in Gap43-luc/gfp mice. This enabled innovative correlation 
of the MRI-determined lesion size to photon fluxes obtained by bioluminescence imaging. Our data 
revealed that following ischemia, Tlr2-deficient mice had higher Gap43 expression and higher levels 
of caspases 3 and 7 activity, which was accompanied by enhanced levels of synaptic plasticity markers 
DLG4 and synaptophysin when compared to wild type controls. Altered inflammation in Tlr2-deficient 
mice was accompanied by enhanced elements of post-stroke repair, in particular during the chronic 
phase of recovery, but also with delayed final consolidation of the brain lesion.
The therapy of stroke patients has been considerably improved since introducing thrombolysis and thrombec-
tomy, as well as applying the stroke unit treatment1,2. Nonetheless, specific therapies which would address the 
long-term consequences of stroke are not yet available. The main reason for the lack of specific therapies is the 
vast complexity of interconnected events following stroke and their progression with time. This is combined with 
challenges of long-term follow-up in preclinical models using laboratory animals3. Thus, both the complexity of 
stroke and the improvement of animal models need to be addressed to design relevant preclinical approaches. 
One such approach, which was applied in the present study, is to follow the consequences of brain lesions through 
time with the use of in vivo imaging, allowing the same group of animals to be evaluated at different time points.
The transient medial cerebral artery occlusion (tMCAO) is used as an animal model for human ischemic 
stroke. This model involves the removal of an inserted filament following 60 minutes of occlusion, which after 
ischemia, allows for reperfusion of the affected territory of the medial cerebral artery. As this model combines 
ischemia with subsequent reperfusion, it could be of particular relevance for patients treated by thrombolysis and 
thrombectomy.
The aim of this study was to analyze the effects of altered innate immunity on an ischemic lesion in the mouse 
brain, with a specific emphasis on the aspects of neuronal stress and repair. The multimodal in vivo imaging 
adopted in this study allowed for longitudinal monitoring of animals for as long as 1 month after the lesion. As a 
model of reduced neuroinflammation, Tlr2-deficient mice were used since previous studies have demonstrated 
the reduced microglial activation and proliferation after ischemic lesion4.
Toll-like receptors (TLRs) are the main mediators of aseptically triggered neuroinflammation5–8. Necrosis 
following ischemia results in the release of danger/damage associated molecular patterns (DAMPs), which are 
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then recognized by TLRs. As TLRs are expressed on the CNS resident microglia, TLR activation triggers the 
subsequent activation of microglia and thus an increase in the transcription of inflammatory cytokines (IFN-β, 
IFN-α, IL-1β i IL-6 via NFkB)5,7,9. As a member of the TLR family, activation of the TLR2 pathway has be shown 
to specifically contribute to microglial proliferation, astrocyte accumulation and recruitment of monocytes/mac-
rophages from the peripheral circulation4,7,10. Tlr2 deficiency results in a reduction of the amount of Insulin like 
growth factor 1 (IGF-1) and Monocyte chemotactic protein 1 (MCP-1), which consequently reduces the number 
of activated resident microglia, as well as decreases the infiltration of CD45high/CD11b+ cells following ischemia9. 
Previous studies of brain ischemia using Tlr2-deficient mice, including our own, have shown that altering neu-
roinflammatory responses did not result in either beneficial or harmful consequences with regards to the lesion 
size, but was in fact a combination of both depending on the time or phase following ischemia5,9. In the acute 
phase, Tlr2 deficiency reduces the volume of the ischemic lesion, however in the later phase, modified inflam-
mation associated with Tlr2 deficiency leads to delayed apoptosis and a larger sized ischemic lesion at later time 
points compared to the wild type (WT) animals4. Altered dynamics of apoptosis can be monitored through the 
activation of its hallmark cleaving enzyme caspase 3 (CASP3) that have been shown to rapidly increase during 
early postischemic responses11. Interestingly, a non-apoptotic role for CASP3 in controlling neuronal cytoskel-
eton components such as actin, MAP2, GAP43, Dbn1 and calmodulin has also been elucidated more recently12. 
Thus, CASP3 activity can be a useful representative indicator of postischemic stress13.
To clarify the combination of beneficial and harmful events related to modulated neuroinflammation due 
to Tlr2 deficiency, this study monitored ischemic brain lesion and its consequences through time by multi-
modal in vivo imaging combining magnetic resonance imaging (MRI), bioluminescence imaging (BLI) and 
caged-luciferin-BLI. MRI modality measured the extent of the stroke using a T2-weighted anatomical scan. 
BLI, based on collecting light released from transgenic animals carrying luciferase reporters when injected with 
luciferin, was used to monitor the activity of Gap43 promoter (Gap43-luc/gfp transgenic mouse) as a marker 
of axonal repair and outgrowth to assess post-stroke axonal remodeling14. Caged-luciferin-BLI is based on the 
application of non-active forms of luciferin. They liberate luciferin (i.e. as from the cage) through the cleavage by 
enzymes, such as caspases. In this study we applied DEVD-aminoluciferin (VivoGlo, Sigma), which after cleavage 
by caspases 3 and 7 (CASP3/7) liberates free luciferin from the DEVD part, enabling it to react with luciferase 
located in the cells of the transgenic animals. As we used Gap43-luc/gfp animals, the signal corresponded to the 
subset of cells expressing Gap43, which at the same time had CASP3/7 activity. Visualizing the cells exhibiting a 
combination of GAP43 and CASP3/7 activities represents a measure of neuronal stress and apoptosis of neurons 
affected by ischemia13.
For this particular study, several mouse lines were created and used. To achieve promoter-dependent lucif-
erase activity in Tlr2-deficient mice, it was necessary to crossbreed the Gap43-luc/gfp transgenic animals with 
mice with loss of function of Tlr2. Moreover, to allow optical imaging of light we used albino variants of C57Bl/6 
mice. As a result a novel transgenic mouse line Gap43/Tlr2−/− (B6-Tyrc-Brd- Tg(Gap43-luc/gfp)- Tlr2tm1Kir/Gaj) 
was created and specifically applied for this study. Subsequently, multimodal in vivo imaging of these mouse lines 
provided simultaneous insight into the evolution of the lesion size, neuronal stress, axonal outgrowth and apop-
tosis. The imaging was complemented by functional tests (weight monitoring, neurological scoring, accelerating 
rotarod, Y-maze, bilateral tactile stimulation (sticky tape) test, and Schallert’s cylinder test), and ex vivo analysis 
of synaptic markers (DLG4, Synaptophysin) by Western Blot.
Using the long-term follow up and standardization of BLI according to the size of ischemic lesion, as measured 
by MRI, we showed that in Tlr2-deficient mice a significant increase in Gap43 and caspase3/7 activity occurred 
in particular during the chronic phase of the brain recovery.
Results
Lower mortality in Tlr2-deficient mice after tMCAO. To compare the consequences of ischemic lesion 
on WT and Tlr2−/− mice, the survival after tMCAO was documented. The survival analysis showed that more 
Tlr2−/− mice survived than WT mice (Fig. 1A). Chances of survival of Tlr2−/− mice analysed by Log-rank 
(Mantel-Cox) test was 2.61 fold higher (P = 0.028) than those of WT animals. Mice (n = 36) were monitored 
throughout the 28 days post ischemia, with the majority of non-survivors lost during the first week (14 mice of 
total 15 non-survivors died during the first week).
To compare functional consequences of ischemic lesion between Tlr2−/− and WT mice, a battery of behav-
ioural tests were used together with body weight measurements (Fig. 1). The data obtained from non-survivors 
were also included in order to identify putative prognostic factors that are impaired in WT compared to Tlr2−/− 
mice (Fig. 1C). The body weight analysis showed a significant decrease in all mice (22% loss from the baseline 
values) 3 days after tMCAO (Fig. 1B). Until day 14, body weight values remained significantly below the baseline, 
but at day 28, all groups regained their starting body weights. This parameter did not significantly differ among 
Tlr2-deficient and WT animals, nor did the weight loss allow for prediction of survival.
Regarding neurological scoring, there was no significant difference between Tlr2−/− and WT mice, nor 
between the survivors and non-survivors. Outliers with high neurological deficits belonged to the non-survivors, 
as the behavioural tests are similar to the assessment necessary to determine ethical humane endpoint15. 
Nevertheless, some of the non-survivors died in spite of having favourable neurological scores (Fig. 1C). Due 
to the nonspecific nature of neurological scoring that is suitable for observing acute behavioural deficits after 
tMCAO, further battery of more sensitive tests addressing sensorimotor recovery, spatial memory and exploring 
activities was applied16.
Out of four additional behavioural tests (accelerating rotarod, Y-maze, Schallert’s cylinder, bilateral tactile 
stimulation), significant differences between WT and Tlr2−/− mice were detected only during bilateral tactile 
stimulation testing using sticky tape on the contralateral forepaws. For the bilateral tactile stimulation test, latency 
after contact with sticky tape until the complete removal of both forepaws was noted. In WT mice, the delayed 
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reactions of the contralateral forepaw resolved with animal recovery, while in Tlr2−/− mice, which initially fared 
better than WTs (latency was shorter), the delayed latency did not improve with time, and it persisted until the 
end of experiment (Fig. 1D). Even though Tlr2−/− mice demonstrated better survival, their functional status as 
measured using behavioural tests was not significantly more impaired compared to their WT controls. This was 
partly due to the larger proportion of deaths in the WT group where only the animals with slight impairment 
survived. Below the significance threshold, in Tlr2−/− mice we observed less movements in Schallert’s cylinder 
and lower endurance on accelerating rotarod.
Combining MRI and BLI as a multimodal approach showed stronger Gap43 expression and 
CASP3 activity after tMCAO in Tlr2-deficient mice. To detect Gap43 expression and CASP3/7 activity 
in vivo, bioluminescence imaging was performed using free D-aminoluciferin and caged-DEVD-luciferin respec-
tively. In terms of Gap43 expression, photon flux measured in Gap43-luc/gfp transgenic mice, Tlr2-deficient mice 
and WT controls showed that at baseline, both mouse groups had the same values of expression. After ischemic 
lesion the expression increased, peaking at day 7, and returned to its baseline values at day 28 (Fig. 2).
The bioluminescent signal mirroring Gap43 expression was significantly higher (P = 0.016) in Tlr2−/− mice 
compared to WT animals at day 14. Due to large variability of the measured values, there was no statistically 
significant difference among the groups of the different genotype at other days, in particular at day 7 (Fig. 2B). 
These data led us to propose a new, ad-hoc hypothesis that the size of the lesion influenced the signal measured 
by BLI, i.e. bigger lesion produced more photons as measured using BLI. This hypothesis was immediately tested 
using MRI data on the ischemic lesion size as they were obtained, in parallel. Ischemic lesion was visualized by 
T2-weighted anatomical scans, with the help of T2-maps to distinguish tissue changes in the ischemic region vs. 
surrounding areas.
MRI data was used to compare brain size between Tlr2−/− and WT mice, with results showing that brain 
sizes measured at baseline did not differ between the groups (data not shown). Moreover, there was no signifi-
cant difference in lesion size between Tlr2−/− and WT mice at any of the time points examined (Fig. 3). Stroke 
area was the largest at 3 days after tMCAO and gradually decreased in size similarly in both groups (nWT = 4; 
nTlr2−/− = 5, imaged at all time points, but the data from non-survivors were included in the analysis as well). 
These data do not corroborate with our previous results obtained by Nissl staining from a separate study, most 
likely, as the number of animals imaged was too low to show the differences9.
MRI data on the lesion size at each time point from the present study was further used to correlate with BLI 
values of Gap43 expression. The correlation was tested and proven to be statistically significant both in Tlr2−/− 
and WT mice (r = 0.438, P = 0.045* for WT, r = 0.430, P = 0.029* for Trl2−/−) (Fig. 3D). This confirmed our 
Figure 1. (A) Tlr2−/− mice survival after ischemic lesion is better than of their wild type (WT) counterparts 
analyzed by Log-rank (Mantel-Cox) test P = 0.037*; (B) Both, Tlr2−/− and WT lose body weight after 
ischemic lesion, and subsequently regain it after 28 days; (C) Mice that reached humane endpoint (grey and 
pale red) (non-survivors, NS) had worse neurological scores than their survivor counterparts. There was no 
significant difference between wild type (WT), and Tlr2−/− mice. (D) Bilateral tactile stimulation test revealed 
decreased latency in sticky tape removal from the contralateral forepaw in acute time points in Tlr2−/− mice 
compared to their wild type (WT) counterparts, but increased time of reaction in the later time points of 14 and 
28 days. ***,** and *marking P < 0.001, P < 0.01, P < 0.05 for differences between WT controls and Tlr2−/− 
controls, respectively. #Are used to mark differences within the same genotype compared to their sham operated 
controls (WT controls vs. WT tMCAO, Tlr2−/− controls vs. Tlr2−/− tMCAO).
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ad-hoc hypothesis and allowed to normalise the photon flux obtained by BLI to the respective lesion size obtained 
by MRI. The time curves of Gap43 expression normalised to lesion size differed clearly by this approach, with 
Gap43 expression in Tlr2-deficient mice being significantly higher at 3 and 14 days post tMCAO when compared 
to WT mice, and at 7 days being borderline significantly different (P = 0.056). Gap43 expression between the two 
groups was comparable only at day 28 (Fig. 3E).
An analogous strategy was applied for caged-luciferin BLI in order to compare CASP3/7 activity between 
Tlr2−/− and WT mice (Fig. 4). Firstly, the original data obtained by caged-luciferin BLI were compared between 
groups, which showed comparable results without visible differences. Moreover, the curves crossing each other 
(Fig. 4C). Secondly, the correlation between lesion size and BLI-obtained photon flux was verified. Indeed, the 
correlation was present for both groups (r = 0.438, P = 0.045* for WT, r = 0.430, P = 0.029* for Trl2−/−; Fig. 4B). 
Finally, the BLI photon flux was normalised according to the lesion size and the time curves of the two groups 
were clearly distinguishable, showing in Tlr2-deficient mice higher CASP3/7 activity in Gap43-expressing cells, 
in particular in the chronic stage of recovery, where the activity was higher at days 14 and 28 (P = 0.008, P = 0.032, 
respectively).
In conclusion, the multimodal approach of combining MRI and BLI resulted in the observation of significant 
differences between the analysed groups, convincingly demonstrating the influence of reduced inflammation on 
Gap-43 expression and CASP3 activity as exhibited in Tlr2-deficient mice.
Higher GAP43 and CASP3 in Tlr2-deficient mice were accompanied by increased expression of 
synaptic markers. To confirm bioluminescence findings, protein levels of GAP43 and CASP3 in the brain of 
mice with ischemic lesion were determined using Western Blot. This was supplemented with the measurement of 
the expression of synaptic markers DLG4 and synaptophysin, indicating overall quantity of synapses, as a direct 
measure of synaptic recovery (Figs 5 and S1).
Levels of GAP43 in WT mice reached its maximum at day 7 post ischemia and then decreased to baseline lev-
els at day 28, in conformity with previous studies14,17. In Tlr2−/− mice, GAP43 values at day 28 were significantly 
higher than at baseline, contrary to the decline as demonstrated in WT mice. Interestingly, GAP43 levels followed 
the dynamics of synaptophysin (Fig. 5D), indicating the connection between axonal outgrowth (as measured by 
GAP43) and synaptic plasticity (as measured by synaptic markers) after tMCAO.
CASP3 quantities rose in both groups, with significantly higher values measured in Tlr2−/− mice when com-
pared to WT animals. At day 28, CASP3 resolved to baseline values in WT mice, while in Tlr2−/− mice CASP3 
activity persisted at significantly higher levels (Fig. 5D).
Western blot analysis of the synaptic proteins DLG4 and synaptophysin showed that the baseline values of 
both were similar in both animal groups, but after tMCAO, DLG4 increased in the Tlr2−/− mice at day 14 and 
remained elevated until day 28, when synaptophysin increased as well. At day 28, both of these proteins were 
expressed at lower levels in the WT group when compared to Tlr2−/− mice. In conclusion, Tlr2-deficiency led 
Figure 2. (A) Representative images of bioluminescence signal imaging using d-aminoluciferin for Gap43-luc-
gfp (WT), and Gap43-luc-gfp-Tlr2−/− (Tlr2−/−) mice. (B) Total photon flux measured for Gap43-luc-gfp 
(WT), and Gap43-luc-gfp-Tlr2−/− (Tlr2−/−) mice showing median and interquartile range.
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to a slower yet higher increase in the expression of GAP43 and synaptic markers, with longer persistence of high 
CASP3 levels than in WT mice.
Discussion
The MCAO stroke model remains the golden standard for bridging the translational gap between basic research 
and clinical applications in spite of inherent variability18. The advantage of the use of modern tools such as mul-
timodal imaging is the ability to counteract variability and provide standardization. In this study, multimodal 
imaging was applied in the analysis of the ischemic brain lesion using MRI, BLI and caged-luciferin BLI. The 
multimodal approach allowed for the normalization of the values of BLI to the size of the ischemic lesion obtained 
by MRI. This provided the analytical power to achieve significant differences between tested (Tlr2-deficient) 
and control groups (WT animals) using a rather small number of animals (n = 5 per group), which in the case 
of using a single modality, would remain a highly underpowered study. This is particularly evident in the case 
of caged-luciferin-BLI, which as a single modality did not reveal any differences, however when adjusted to the 
lesion size, demonstrated differences that were clearly pronounced and statistically significant.
Subsequently, the major outcome of this study was establishing a new way of combining MRI and BLI, based 
on the correlation of the MRI-determined lesion size with the BLI and caged-luciferin BLI photon flux obtained 
at the same time point. This innovative approach was applied to measure Gap43 expression and CASP3/7 activity, 
and correlation with the ischemic lesion size was confirmed for both markers. This showed that the combination 
of MRI and BLI could be used for the transgenic reporters, where promoter of interest controls luciferase expres-
sion, as for the enzymatic approach, where the enzyme of interest cleaves the caged luciferin and releases its free 
form. Nonetheless, we cannot claim that this approach would work for any bioluminescent in vivo marker, as 
the correlation between modalities would need to be firstly verified and this would then indicate if a multimodal 
approach could be more informative than using a single imaging modality.
When discussing the clinical relevance of MCAO to the ischemic stroke, the variability of the lesion size 
is similar in mice and humans. Hence, if we could overcome the issue of lesion variability in a constructive 
Figure 3. (A) Representative MRI T2 maps of ishemic lesion in WT and Tlr2−/− mice. (B) Total stroke area 
measured by a blinded rater shows gradual decrease in ischemic volume with no differences between the WT 
and Tlr2−/− mice. (C) Stroke area adjusted for oedema index shows the volume of ischemic lesion used for 
further calculation of correlations. (D) Correlations of BLI signal using d-aminoluciferin and Stroke area by 
genotype. (E) Total Photon Flux adjusted per stroke Area measured by MRI shows increased BLI signal in 
Tlr2−/− mice compared to their WT counterparts in acute and chronic time point (3 and 14 days).
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way, namely, by measuring the deviation of the every animal, then the study design would provide the answers 
to experimental questions without increasing the number of animals used. This would potentially enhance the 
clinical relevance of the MCAO model in preclinical studies of ischemic stroke. Our results in the present study 
suggest that multimodal imaging may contribute in this direction of overcoming lesion variability and that infor-
mation on lesion size obtained by MRI can be informative for other imaging modalities (and eventually other 
type of measurements). Moreover, this endorses the reinforcement of regulatory bodies requesting results with 
limited number of animals19. It is important not to jeopardize studies by reducing the number of animals used, 
and our multimodal imaging approach in the present study provides a valuable alternative.
Neuroinflammation resulting from ischemia reperfusion injury was altered in Tlr2-deficient mice when com-
pared to WT mice. Several markers measured in the present study were upregulated in a time-dependent manner, 
namely, GAP43, CASP3/7, DLG4 and synaptophysin. Gap43 expression was increased in Tlr2-deficient mice 
compared to WT controls, suggesting an augmented attempt of neural cells to rearrange their axons. Removing 
damaged neurons by apoptosis is another way of repair shown by CASP3/7 activity. In this study, this visualiza-
tion of apoptosis was not wide-ranging, as only a subset of Gap43-luc-expressing cells was available for imaging. 
While caspase-7 is expressed on microglia during neuroinflammation, caspase-3 is a more dominant effector of 
the caspase cascade in neurons20,21. Therefore the signal harvested from GAP43-luc-gfp mice can be attributed 
predominantly to the cleaved caspase-3.
Caged-luciferin BLI using DEVD-aminoluciferin was previously shown as feasible approach in measuring 
caspases after ischemic lesion. The co-localization of GAP43 and CASP3 is not only specific for the visualiza-
tion of apoptotic cells, but it also corresponds to neurons in stress13. When caged-luciferin BLI was compared 
to Western blot results of CASP3, Tlr2-deficient mice had higher protein levels than the WT controls, but the 
time-curves were not exactly the same. The observed difference can be caused by the fact that Western blot 
measured total brain CASP3, while caged-luciferase BLI measured only the subset present in Gap43 cells, where 
the signal decreased in the late time points. Taking into account the intracellular roles of CASP3 (apoptosis, 
pruning) and GAP43 (sprouting), the caged-luciferase BLI signal may be interpreted as the amount of neuronal 
stress in the early phase after ischemic lesion, and consolidation and repair in the later phase. This was confirmed 
using the markers of synaptic plasticity (DLG4, synaptophysin), which increased at the chronic time points 
in Tlr2-deficient mice in comparison to WT mice. Together with lower mortality in Tlr2-deficient mice, this 
remains in consistency with previous findings of delayed apoptosis of neurons and different evolution of repair 
in these mice4,5.
The question that remained unsolved in this study is whether the mice with an altered innate immunity 
response and enhanced elements of repair do indeed recover better than the WT controls. The neurological scor-
ing and the behavioral tests did not show functional improvement, moreover, in the bilateral tactile stimulation, 
Figure 4. (A) BLI imaging after VivoGloTM injection of representative Gap43-luc-gfp (WT), and Gap43-luc-
gfp-Tlr2−/− (Tlr2−/−) mice; (B) VivoGloTM total photon flux in correlation with Stroke Area measured 
by MRI. (C) VivoGloTM total photon flux dynamics (D) VivoGloTM total photon flux adjusted to Stroke area 
measured by MRI indicating statistically significant increase of BLI signal for Tlr2−/− mice at Days 14 and 28.
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Tlr2-deficient mice were worse in the chronic phase than the WT controls. This controversial outcome has previ-
ously been reported where delayed apoptosis in the Tlr2-deficient mice was accompanied by the larger ischemic 
lesion in the chronic phase9. The enhanced caspase activity actually delayed the final consolidation of the lesion, 
and perhaps the final verdict could be made only after a longer analysis period than the 28 days assessed in the 
present study.
In conclusion, in the acute phase following ischemia, Tlr2-deficient mice seem to be protected from early 
deleterious consequences of ischemic lesion and have less mortality than their WT counterparts. In the chronic 
phase, they have higher expression of markers for neural repair, resulting in prolonged brain remodeling and 
delay of final consolidation of the lesion. The application of multimodal imaging allowed for a longitudinal study 
of the measured markers without the need for an increase in the number of animals used. Therefore, multimodal 
imaging offers a realistic possibility for the assessment of complex post-stroke events, with the potential for the 
evaluation of novel medical interventions (drugs, patient rehabilitation and stem cells).
Materials and Methods
Animals. All animal handling and surgery was approved by the Ethics Committee of the University of Zagreb, 
School of Medicine. All experiments were performed in accordance with relevant guidelines and regulations.
The experiments were carried out on 12–16 weeks old male mice bred at the animal facility of the Croatian 
Institute for Brain Research. B6N-Tyrc-Brd/BrdCrCrl represents the albino variant of the C57Bl/6 inbred strain. 
B6-Tg(Gap43-luc/gfp)/Kri generated by Kriz’s research group has luciferase and GFP reporters under the control 
of the Gap43 promoter14. B6.129-Tlr2tm1Kir/J line represents loss of function of Tlr2 gene4.
For the purpose of this study we created new mouse lines. B6-Tg(Gap43-luc/gfp) 10Kri was mated with 
B6N-Tyrc-Brd/BrdCrCrl to bring the transgenic line onto an albino background resulting with B6-Tyrc-Brd- 
Tg(Gap43-luc/gfp)/Gaj. This mouse line was then mated further with B6.129-Tlr2tm1Kir/J mice in order 
to obtain mice with loss of function of Tlr2, which also have the Gap43 transgene and are on the albino B6 
background, allowing to follow Gap43 expression in the knock-out mice. The resultant mouse line was 
B6-Tyrc-Brd-Tg(Gap43-luc/gfp)- Tlr2tm1Kir /Gaj.
Subsequently, in this study we compared loss of Tlr2 function (depicted as Tlr2−/−) with their no loss 
counterparts (depicted as WT). Both mouse lines were also Gap43 transgenics on an albino B6 background, 
i.e. B6-Tyrc-Brd- Tg(Gap43-luc/gfp)- Tlr2tm1Kir/Gaj (depicted as Tlr2−/−) was compared to B6-Tyrc-Brd- 
Tg(Gap43-luc/gfp)/Gaj (depicted as WT).
Figure 5. Western Blot with analysis per time point of WT and TLR−/− showing median and interquartile 
ranges with statistically significant differences at chronic time points for GAP43 and CASP3, as well as for 
synaptic markers of DLG4 and synaptophysin. ***,** and *marking P < 0.001, P < 0.01, P < 0.05 for differences 
between WT controls and Tlr2−/− controls, respectively. The blots shown here were cut from the bigger gel, 
therefore boxed here, and the full-length blots were provided in Figure S1.
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The animals were genotyped by polymerase chain reaction (PCR) for detection of the luciferase and Tlr2 gene 
as suggested by Jackson Laboratory and previously described14,22.
Transient middle cerebral artery occlusion (tMCAO). For inducing unilateral ischemic lesion of the 
brain, we used the tMCAO method. Mice were anaesthetised with 2% isoflurane inhalation anaesthesia. An intra-
luminal silicon-coated filament was introduced in the left middle cerebral artery for 1 h followed by reperfusion 
as previously described23. Sham operated animals were subjected to the anaesthesia and filament introduction/
retrieval without an occlusion period.
Behavioral tests. To compare functional recovery after tMCAO between experimental groups we used 5 
different tests: neurological deficit scoring (56 points neuroscore), accelerating rotarod, Y-maze, bilateral tactile 
stimulation (sticky tape) test, and Schallert’s cylinder test. In order for the laboratory animals to get used to the 
rater, all the tests were started 2 weeks before the tMCAO and performed on a weekly basis. After the surgery, 
behaviour was tested on the day 1, 7, 14, 21 and 28.
In Vivo Bioluminescence imaging (BLI). GAP43 transgenic mice were anesthetized with 2% isoflurane 
in 100% oxygen in an induction chamber, and injected intrapretioneally (i.p.) with different luciferase sub-
strates on consecutive days: VivoGlo (VivoGlo Caspase 3/7 Substrate; Z-DEVD-Aminoluciferin Sodium Salt, 
Promega, Madison, WI, USA) followed by luciferin (XenoLight D-Luciferin - K+ Salt Bioluminescent Substrate, 
PerkinElmer, Waltham, MA, USA), 24 hours after4,13. Animals were individually placed in the heated light-tight 
imaging chamber of IVIS SPECTRUM Imaging System (PerkinElmer, Waltham, MA, USA) with continuous 
inhalation anaesthesia of 2% isoflurane–oxygen mixture at 1 L/min. To obtain the baseline values, imaging was 
done 3 days before the surgery and then 3, 7, 14, and 28 days after tMCAO. Total flux of photons was measured 
using the Living Image 4.3 acquisition and imaging software (PerkinElmer, Waltham, MA, USA), as described 
previously13.
Magnetic resonance imaging (MRI). Animals were imaged 3 days before tMCAO and at 3, 14 and 28 days 
after tMCAO for establishing baseline and follow up images, respectively.
Magnetic resonance imaging was performed on a 7 T system (BioSpec 70/20 USR with Paravision 6.0.1. 
software version, Bruker Biospin, Germany) in a Tx/Rx configuration, using an 86 mm transmit volume coil 
(MT0381, Bruker Biospin, Germany) for transmitting (Tx) and a 2-element mouse brain surface receive coil 
(MT0042, Bruker Biospin, Germany) for receiving (Rx). The animals were placed in a supine position inside a 
water-heated Bruker mouse bed (Bruker, Germany), and the position of their head was secured by help of the 
tooth bar and ear bars.
Prior to imaging, animals were anesthetised in an induction chamber with a mixture of 70/30% N2/O2 con-
taining 4% isoflurane (Isoflurane, Abbott, UK). During scans, anaesthesia was maintained with a delivery of 
1–1.5% isoflurane in the same N2/O2 mixture, and monitored via observing the respiratory rate with an optical 
probe (Medres, Cologne, Germany). The respiratory rate was kept in the range 80–100 breath/min during the 
whole scan. Body temperature of the animal was maintained at 37 ± 0.5 °C by controlling the temperature of the 
water heated bed and an additional body cover with a feedback-controlled circulating heating pump and was 
monitored using a MR-compatible rectal temperature probe (Medres, Cologne, Germany).
The scan protocol consisted of a preparatory phase and main scans. In the preparatory phase, first a 
low-resolution GE pilot scan (Multi-Slice Localizer) was performed, followed by an additional TSE scan 
(TurboRARE) in the sagittal plane to enable precise longitudinal alignment of the slices, and an additional 
shimming over the region of interest using MAPSHIM sequence. The main scans included a high-resolution 
T2-weighted anatomical scan for measuring the extent of the stroke and a T2-map scan protocol to assess 
the level of tissue change in the ischemic region. T2 maps were calculated from measured data using built-in 
post-processing macros of Paravision software.
In all main scans, the field of view was set to 16 × 10 mm, and the slice thickness and gap between slices were 
0.5 mm and 0.1 mm, respectively. The slice package extended from rhinal fissure to the anterior part of the cer-
ebellum and was aligned, in all time points, on the second slice, which was placed on the rhinal fissure. Further 
scan parameters were set as follows:
High-resolution T2-weighted scan. Turbo Spin-Echo sequence (TurboRARE, RARE = 8), TR/TE = 3000/30 ms, 
Nex = 6, In-plane resolution = 90 × 90 um, total time = 4 min.
T2-map scan. Multi-echo Spin-Echo sequence (MSME, Necho = 15), TR/TE = 2500/(8, 16, …, 120 ms), 
Nex = 5, In-plane resolution = 111 × 111 um, total time = 19 min.
Total duration of the imaging protocol, including anaesthesia and positioning, was around 50 min.
Segmentation was performed by manual delineation of ipsilateral and contralateral hemisphere and ischemic 
lesion in ImageJ1 (NIH, Bethesda, USA) taking into account possible stroke density differences and contiguity of 
the lesion area throughout the MRI image stack. MRI exclusion criteria were applied during the first post-tMCAO 
imaging and consisted of un-apparent lesion, lesion size below 20 pixels, and haemorrhagic conversion of 
ischemic lesion.
Western blot. To detect levels of proteins involved in inflammation and regeneration after brain ischemia, 
mice stroke affected lateral portions of the hemisphere were isolated and snap-frozen in liquid nitrogen and 
stored at −80 °C. Proteins were isolated by mechanical homogenisation in SDS-urea-β-mercaptoethanol solution 
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containing proteinase inhibitor on ice. Electrophoresis and transfer on the PVDF-membrane was done using 
BioRad Mini-PROTEAN3 System (BioRad, Hercules, CA, USA).
Primary antibodies were β3-Tubulin (5568 S, Cell Signalling Technology, Beverly, MA, USA) as a loading con-
trol, DLG4 (PSD95) (3450, Cell Signalling Technology Beverly, MA, USA), GAP43 (AB5220, Merck, Kenilworth, 
NJ, USA), synaptophysin clone SY38 (MAB5258, Merck, Kenilworth, NJ, USA), and anti-cleaved CASP3 (Cell 
Signaling, Danvers, MA, USA). Secondary antibodies were goat anti-mouse, and goat anti-rabbit (32430 and 
A27011, Thermo Fisher Scientific, Waltham, MA, USA). The chemiluminiscent signal achieved by Western 
Lightning – EXL Enhanced Chemiluminiscence Substrate (Perkin Elmer, Waltham, MA, USA) was imaged by 
ChemiDoc MP System (BioRad, Hercules, CA, USA) and analysed using Image Lab Software (BioRad, Hercules, 
CA, USA).
Experimental groups. For behavioural analysis 4 groups were followed: Gap43 sham (5) and 
Gap43Tlr2−/− sham (5) as controls, and Gap43 (6) and Gap43Tlr2−/− (6) mice that underwent the tMCAO. 
During the experiment, 4 Gap43 and 2 Gap43Tlr2−/− mice had an early humane endpoint (HEp) due to 
tMCAO, and 1 Gap43 mouse was retroactively excluded from the experiment due to haemorrhage established 
during the brain isolation (total 29 mice).
For Western Blot, 5 mice were used per group (Gap43 and Gap43Tlr2−/−) to determine relative protein val-
ues for the baseline (naïve controls, Day 0), and for 3,7,14 and 28 days post tMCAO (total 50 mice). There were 
no sham-operated animals whose tissue was isolated at each time point, due to the reduction of the number of 
animals, and as a control only naïve mice were used and included on the graph as Day 0.
For in vivo imaging 15 Gap43 animals were used, with 3 of them had no detectable lesion on MRI and there-
fore were removed from the experiment. Furthermore, 8 mice from that group reached the humane end point 
before the day 28 (Non-Survivors). Out of 9 Gap43Tlr2−/− mice enrolling the imaging, only 1 reached the 
humane endpoint before the day 28, and 3 animals were removed from the experiment due to the MRI exclusion 
criteria for the lesion identification (total 26 mice).
Total number of mice used was 103.
Statistical analysis. Survival proportions were analysed by Log-rank (Mantel-Cox) test.
Body weight, neurological deficit scoring, behavioural analysis, MRI and BLI data were analysed by 2-way 
analysis of variance of 4 groups followed by Bonferronni’s multiple comparison test.
For MRI data, BLI data, and neurological deficit score correlation, graphs were assembled observing the 
R2 values of correlation coefficient, and data were analysed by comparing the 2 groups at each time point by 
Mann-Whitney test.
For Western blot results Mann-Whitney test was used to compare the protein quantities from the samples 
collected at different time points and between the different groups (WT, Tlr2−/−).
Differences were considered statistically significant with P < 0.05.
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